A Double-Blind, Randomized, Placebo-Controlled, Single- And-Multiple-Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CRN01941 in Healthy Volunteers

This is a Phase 1, double-blind, randomized, placebo-controlled, single-dose and multiple-dose study of CRN01941 in up to 119 healthy male and female subjects. This single-center study will be conducted in 3 parts: a single-ascending dose phase (up to 8 cohorts, 8 subjects/cohort), a multiple-ascending dose phase (up to 5 cohorts, 9 subjects/cohort), and single dose phase in elderly subjects (1 cohort, 10 subjects).

Start Date29 Apr 2019

Sponsor / Collaborator

Crinetics Pharmaceuticals, Inc.

NCT01143298 / CompletedPhase 1

LEO 27847 - A Single Dose Bioavailability Study of Oral Solid Dosage Form Versus Oral Solution Including Fed Versus Fasted State in Healthy Male Subjects

The purpose of this phase 1 study is to determine the relative bioavailability following single oral dose administration of LEO 27847 solution compared to LEO 27847 tablets in healthy male subjects as well as to determine the effect of food on the single oral dose pharmacokinetics of LEO 27847 tablets in healthy male subjects.

Start Date01 Jun 2010

Sponsor / Collaborator

Leo Pharma, Inc.

NCT02265302 / CompletedPhase 1

A Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability, Biological Effects and Preliminary Pharmacokinetics of Increasing Single Oral Doses of BIIL 284 BS (Dose Range: 0.025 mg - 75 mg PSE Solution, 25 mg, 75 mg, 250 mg and 750 mg WIF Tablets) in Healthy Male Volunteers as Well as Food Effects at 75 mg (WIF Tablet)

Study to obtain information about the safety and tolerability of BIIL 248 BS, to find the pharmacologically active dose range for the two formulations PSE 1% and WIF tablets by determination of the surrogate marker CD11b (= Mac-1) and to obtain preliminary pharmacokinetic data as well as first information on food effects after administration of the 75 mg WIF tablet in healthy male volunteers

Start Date01 Jun 1998

Sponsor / Collaborator

Boehringer Ingelheim GmbH

100 Clinical Results associated with Armillariella Oral Solution

100 Translational Medicine associated with Armillariella Oral Solution

100 Patents (Medical) associated with Armillariella Oral Solution

100 Deals associated with Armillariella Oral Solution

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Cholangitis	CN	Hefei Chengzhi Biological Pharmaceutical Co., Ltd	01 Jan 2002
Cholecystitis	CN	Hefei Chengzhi Biological Pharmaceutical Co., Ltd	01 Jan 2002
Gastritis	CN	Hefei Chengzhi Biological Pharmaceutical Co., Ltd	01 Jan 2002
Hepatitis	CN	Hefei Chengzhi Biological Pharmaceutical Co., Ltd	01 Jan 2002
Leukopenia	CN	Hefei Chengzhi Biological Pharmaceutical Co., Ltd	01 Jan 2002

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Armillariella Oral Solution

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation